Redefining the role of biomarkers in heart failure trials: expert consensus document.
Publication
, Journal Article
Kramer, F; Sabbah, HN; Januzzi, JJ; Zannad, F; Peter van Tintelen, J; Schelbert, EB; Kim, RJ; Milting, H; Vonk, R; Neudeck, B; Clark, R ...
Published in: Heart Fail Rev
May 2017
Heart failure is a growing cardiovascular disease with significant epidemiological, clinical, and societal implications and represents a high unmet need. Strong efforts are currently underway by academic and industrial researchers to develop novel treatments for heart failure. Biomarkers play an important role in patient selection and monitoring in drug trials and in clinical management. The present review gives an overview of the role of available molecular, imaging, and device-derived digital biomarkers in heart failure drug development and highlights capabilities and limitations of biomarker use in this context.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Heart Fail Rev
DOI
EISSN
1573-7322
Publication Date
May 2017
Volume
22
Issue
3
Start / End Page
263 / 277
Location
United States
Related Subject Headings
- Patient Selection
- Humans
- Heart Failure
- Disease Management
- Diagnostic Imaging
- Consensus
- Clinical Trials as Topic
- Cardiovascular System & Hematology
- Biomarkers
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Kramer, F., Sabbah, H. N., Januzzi, J. J., Zannad, F., Peter van Tintelen, J., Schelbert, E. B., … Gheorghiade, M. (2017). Redefining the role of biomarkers in heart failure trials: expert consensus document. Heart Fail Rev, 22(3), 263–277. https://doi.org/10.1007/s10741-017-9608-5
Kramer, Frank, Hani N. Sabbah, James J. Januzzi, Faiez Zannad, J. Peter van Tintelen, Erik B. Schelbert, Raymond J. Kim, et al. “Redefining the role of biomarkers in heart failure trials: expert consensus document.” Heart Fail Rev 22, no. 3 (May 2017): 263–77. https://doi.org/10.1007/s10741-017-9608-5.
Kramer F, Sabbah HN, Januzzi JJ, Zannad F, Peter van Tintelen J, Schelbert EB, et al. Redefining the role of biomarkers in heart failure trials: expert consensus document. Heart Fail Rev. 2017 May;22(3):263–77.
Kramer, Frank, et al. “Redefining the role of biomarkers in heart failure trials: expert consensus document.” Heart Fail Rev, vol. 22, no. 3, May 2017, pp. 263–77. Pubmed, doi:10.1007/s10741-017-9608-5.
Kramer F, Sabbah HN, Januzzi JJ, Zannad F, Peter van Tintelen J, Schelbert EB, Kim RJ, Milting H, Vonk R, Neudeck B, Clark R, Witte K, Dinh W, Pieske B, Butler J, Gheorghiade M. Redefining the role of biomarkers in heart failure trials: expert consensus document. Heart Fail Rev. 2017 May;22(3):263–277.
Published In
Heart Fail Rev
DOI
EISSN
1573-7322
Publication Date
May 2017
Volume
22
Issue
3
Start / End Page
263 / 277
Location
United States
Related Subject Headings
- Patient Selection
- Humans
- Heart Failure
- Disease Management
- Diagnostic Imaging
- Consensus
- Clinical Trials as Topic
- Cardiovascular System & Hematology
- Biomarkers
- 3201 Cardiovascular medicine and haematology